AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23616112 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of preferences for colored objects during exposure
Number of subjects: 0
Study 23616112 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to colored objects with a 24-hour delay
Number of subjects: 0
Study 23616112 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining colored objects instead of seeing them
Number of subjects: 0
Study 21515003 — intervention group
Group type: EXPERIMENTAL
Intervention: Camel Snus
Number of subjects: 0
Study 21515003 — intervention group
Group type: EXPERIMENTAL
Intervention: General Snus (high nicotine)
Number of subjects: 0
Study 21515003 — intervention group
Group type: COMPARATOR
Intervention: Other tobacco products (Camel Snus, Marlboro Snus, Stonewall, Ariva)
Number of subjects: 0
Study 19083662 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray and stretch treatment (vapocoolant blend of pentafluoropropane and tetrafluoroethane)
Number of subjects: 30
Study 19083662 — intervention group
Group type: COMPARATOR
Intervention: Stretch only control group
Number of subjects: 30
Study 19083662 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray and stretch treatment
Number of subjects: 30
Study 16451149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask (ILMA)
Number of subjects: 96
Study 16451149 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 96
Study 16451149 — intervention group
Group type: EXPERIMENTAL
Intervention: CobraPLA (COB)
Number of subjects: 96
Study 16451149 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenation and ventilation parameters
Number of subjects: 96
Study 12964946 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation (nurse-facilitated, manual-based using the Heart Manual)
Number of subjects: 650
Study 12964946 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation (comprehensive cardiac rehabilitation in an out-patient setting)
Number of subjects: 650
Study 10613781 — intervention group
Group type: EXPERIMENTAL
Intervention: Assist/control ventilation (A/C)
Number of subjects: 30
Study 10613781 — intervention group
Group type: COMPARATOR
Intervention: Volume-targeted IMV
Number of subjects: 30
Study 10613781 — intervention group
Group type: COMPARATOR
Intervention: Synchronized IMV (SIMV)
Number of subjects: 30
Study 9083601 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-interactive (classroom curricula + parent-interactive component)
Number of subjects: 2392
Study 9083601 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent non-interactive (classroom curricula only)
Number of subjects: 2392
Study 9083601 — intervention group
Group type: COMPARATOR
Intervention: Control (basic AIDS education ordinarily provided by the school)
Number of subjects: 2392
Study 8181546 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscous chemically‐cured sealant (Maximum Cure)
Number of subjects: 80
Study 8181546 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐viscous visible light‐cured sealant (Transbond resin)
Number of subjects: 80
Study 8181546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sealant)
Number of subjects: 80
Study 3372910 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 units of intravenous glucagon
Number of subjects: 8
Study 3372910 — intervention group
Group type: COMPARATOR
Intervention: 2 ml of saline (placebo)
Number of subjects: 8
Study 28847438 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5h training intervention about patient education (video observation, simulated patient practice, structured feedback)
Number of subjects: 164
Study 28847438 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5h training intervention about patient education
Number of subjects: 164
Study 28847438 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no training)
Number of subjects: 164
Study 27855097 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO treatment at the original dose plus intravenous iron dextran 200 mg every 3 weeks (Q3W) for 15 weeks
Number of subjects: 603
Study 27855097 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO treatment at the original dose plus intravenous iron dextran 100 mg, twice a week for 5 weeks
Number of subjects: 603
Study 27855097 — intervention group
Group type: COMPARATOR
Intervention: Doubling the EPO dose without preplanned iron supplementation
Number of subjects: 603
Study 27855097 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 603
Study 25354103 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-unit cord-blood transplantation
Number of subjects: 224
Study 25354103 — intervention group
Group type: COMPARATOR
Intervention: Single-unit cord-blood transplantation
Number of subjects: 224
Study 22836063 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous accelerated irradiation (CAIR: once per day, 7 days per week)
Number of subjects: 345
Study 22836063 — intervention group
Group type: COMPARATOR
Intervention: Concomitant accelerated boost (CB: once per day, 3 days per week, and twice per day, 2 days per week)
Number of subjects: 345
Study 22836063 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 345
Study 20390354 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative bowel preparation (BP)
Number of subjects: 86
Study 20390354 — intervention group
Group type: COMPARATOR
Intervention: Surgery without bowel preparation (BP)
Number of subjects: 86
Study 17942331 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink II (groups 1, 3, 5, and 7)
Number of subjects: 80
Study 17942331 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem (groups 2, 4, 6, and 8)
Number of subjects: 80
Study 16888454 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation (20 g.d(‐1) for 7 d then 5 g.d(‐1) for 4‐7 d)
Number of subjects: 7
Study 16888454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 7
Study 11991696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative colour duplex marking
Number of subjects: 149
Study 11991696 — intervention group
Group type: COMPARATOR
Intervention: Varicose vein surgery without pre-operative marking
Number of subjects: 149
Study 9789579 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric training of the elbow flexor muscles
Number of subjects: 54
Study 9789579 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined isometric training
Number of subjects: 54
Study 9789579 — intervention group
Group type: COMPARATOR
Intervention: Control task involving lower limbs
Number of subjects: 54
Study 7633103 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced MT-GRE images
Number of subjects: 30
Study 7633103 — intervention group
Group type: COMPARATOR
Intervention: Enhanced GRE images
Number of subjects: 30
Study 7633103 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of enhanced MT-GRE images
Number of subjects: 30
Study 2919775 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine epidural analgesia (N = 20) for 26‐30 hours
Number of subjects: 40
Study 2919775 — intervention group
Group type: COMPARATOR
Intervention: Ketobemidone (control group, N = 20) for postoperative pain relief
Number of subjects: 40
Study 333852 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg nalbuphine
Number of subjects: 100
Study 333852 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.14 mg/kg nalbuphine
Number of subjects: 100
Study 333852 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg pentazocine
Number of subjects: 100
Study 333852 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg pentazocine
Number of subjects: 100
Study 333852 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine
Number of subjects: 100
Study 333852 — intervention group
Group type: EXPERIMENTAL
Intervention: pentazocine
Number of subjects: 100
Study 333852 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine and pentazocine
Number of subjects: 100
Study 6759060 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting propranolol (160 mg once daily)
Number of subjects: 20
Study 6759060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release clonidine (0.25 mg once daily)
Number of subjects: 20
Study 29134819 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention program
Number of subjects: 76
Study 29134819 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study 29343076 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin 40 mg daily for 1 day before to 3 days after contrast administration
Number of subjects: 496
Study 29343076 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose atorvastatin 10 mg daily for 1 day before to 3 days after contrast administration
Number of subjects: 496
Study 26938555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education sessions (12-week program)
Number of subjects: 353
Study 25066648 — intervention group
Group type: EXPERIMENTAL
Intervention: CDT including Bandage
Number of subjects: 45
Study 25066648 — intervention group
Group type: EXPERIMENTAL
Intervention: CDT including Bandage + Kinesio Tape(®)
Number of subjects: 45
Study 25066648 — intervention group
Group type: EXPERIMENTAL
Intervention: CDT including Kinesio Tape(®) without bandage
Number of subjects: 45
Study 22351696 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF (cyclophosphamide-epirubicin-fluorouracil)
Number of subjects: 476
Study 22351696 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide-methotrexate-fluorouracil)
Number of subjects: 476
Study 22351696 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF
Number of subjects: 476
Study 22351696 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 476
Study 19028044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg once in the morning for 7 days post-operation)
Number of subjects: 1126
Study 19028044 — intervention group
Group type: COMPARATOR
Intervention: Standard pre- and postoperative therapy (control group B)
Number of subjects: 1126
Study 19028044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 1126
Study 17574951 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck muscle endurance (NME) treatment for patients with NP
Number of subjects: 203
Study 17574951 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck muscle endurance (NME) treatment for patients with ACDF
Number of subjects: 203
Study 17574951 — intervention group
Group type: COMPARATOR
Intervention: NME comparison between patients and controls
Number of subjects: 203
Study 17574951 — intervention group
Group type: EXPERIMENTAL
Intervention: NME comparison between female patients with ACDF and NP
Number of subjects: 203
Study 17574951 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion/extension ratio in patients with NP
Number of subjects: 203
Study 17574951 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion/extension ratio in patients with ACDF
Number of subjects: 203
Study 17574951 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between NME and Neck Disability Index
Number of subjects: 203
Study 15237710 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 39
Study 15237710 — intervention group
Group type: COMPARATOR
Intervention: Control children
Number of subjects: 39
Study 11933130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol (360 mg per day)
Number of subjects: 40
Study 11933130 — intervention group
Group type: COMPARATOR
Intervention: Venostasin (600 mg per day)
Number of subjects: 40
Study 9862573 — intervention group
Group type: EXPERIMENTAL
Intervention: Linomide 5 mg or 10 mg p.o. daily for 2 weeks
Number of subjects: 31
Study 9862573 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha‐interferon added at 3 MU s.c. three times weekly, escalating by 3 MU per week up to 12 MU
Number of subjects: 31
Study 9862573 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Linomide and alpha‐interferon
Number of subjects: 31
Study 9862573 — intervention group
Group type: EXPERIMENTAL
Intervention: Linomide 5 mg for 2 weeks
Number of subjects: 31
Study 9862573 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response to treatment
Number of subjects: 31
Study 8770850 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t-PA) given in an accelerated dosing regimen
Number of subjects: 60000
Study 8770850 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 60000
Study 8770850 — intervention group
Group type: COMPARATOR
Intervention: No reperfusion therapy
Number of subjects: 60000
Study 2165889 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breaths during rest
Number of subjects: 0
Study 2165889 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breaths during 50 W exercise
Number of subjects: 0
Study 20551 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg BS 100‐141
Number of subjects: 24
Study 20551 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg BS 100‐141
Number of subjects: 24
Study 20551 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg BS 100‐141 (crossover study)
Number of subjects: 24
Study 20551 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg BS 100‐141 (crossover study)
Number of subjects: 24
Study 20551 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 mg clonidine (crossover study)
Number of subjects: 24
Study 20551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31326730 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 258
Study 31326730 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard therapy)
Number of subjects: 258
Study 28593415 — intervention group
Group type: EXPERIMENTAL
Intervention: FROI with enhanced haptic feedback activated
Number of subjects: 20
Study 28593415 — intervention group
Group type: COMPARATOR
Intervention: Conventional grasper
Number of subjects: 20
Study 28593415 — intervention group
Group type: COMPARATOR
Intervention: FROI with enhanced haptic feedback deactivated
Number of subjects: 20
Study 26307603 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2963016 (LY IGlar)
Number of subjects: 211
Study 26307603 — intervention group
Group type: COMPARATOR
Intervention: Lantus (IGlar)
Number of subjects: 211
Study 24880800 — intervention group
Group type: EXPERIMENTAL
Intervention: pegnivacogin
Number of subjects: 32
Study 24880800 — intervention group
Group type: COMPARATOR
Intervention: anivamersen
Number of subjects: 32
Study 21635359 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort
Number of subjects: 12
Study 19708803 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg three times daily (TID)
Number of subjects: 0
Study 19708803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17561929 — intervention group
Group type: EXPERIMENTAL
Intervention: levocetirizine 0.125 mg/kg
Number of subjects: 510
Study 17561929 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 510
Study 15194910 — intervention group
Group type: EXPERIMENTAL
Intervention: VSOP-C184 (0.015, 0.045, or 0.075 mmol Fe/kg)
Number of subjects: 18
Study 15194910 — intervention group
Group type: EXPERIMENTAL
Intervention: VSOP-C184 (0.045 mmol Fe/kg)
Number of subjects: 18
Study 15194910 — intervention group
Group type: EXPERIMENTAL
Intervention: VSOP-C184 (0.075 mmol Fe/kg)
Number of subjects: 18
Study 15194910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11897984 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate (BDP) 168, 672, and 1344 microg/day (n = 15)
Number of subjects: 30
Study 11897984 — intervention group
Group type: EXPERIMENTAL
Intervention: fluticasone propionate (FP) 88, 352, and 704 microg/day (n = 15)
Number of subjects: 30
Study 11897984 — intervention group
Group type: EXPERIMENTAL
Intervention: fluticasone propionate (FP) dry powder inhaler (DPI) 2000 microg/day
Number of subjects: 30
Study 11897984 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate (BDP) and fluticasone propionate (FP)
Number of subjects: 30
Study 11897984 — intervention group
Group type: EXPERIMENTAL
Intervention: High exhaled nitric oxide
Number of subjects: 30
Study 11897984 — intervention group
Group type: EXPERIMENTAL
Intervention: High bronchodilator reversibility
Number of subjects: 30
Study 11897984 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FEV(1)/forced vital capacity ratio
Number of subjects: 30
Study 11897984 — intervention group
Group type: EXPERIMENTAL
Intervention: High sputum eosinophil levels
Number of subjects: 30
Study 11897984 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age at onset of asthma
Number of subjects: 30
Study 9854761 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical exercise therapy
Number of subjects: 208
Study 9854761 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Number of subjects: 208
Study 9854761 — intervention group
Group type: COMPARATOR
Intervention: Self-exercise
Number of subjects: 208
Study 9854761 — intervention group
Group type: COMPARATOR
Intervention: All intervention groups
Number of subjects: 208
Study 8582540 — intervention group
Group type: EXPERIMENTAL
Intervention: Darglitazone 25 mg once a day for 14 days
Number of subjects: 19
Study 8582540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2102672 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail bed excision (Group A)
Number of subjects: 31
Study 2102672 — intervention group
Group type: COMPARATOR
Intervention: Nail bed phenolization in addition to excision (Group B)
Number of subjects: 31
Study 355602 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (mean dose 45 mg daily)
Number of subjects: 12
Study 31870811 — intervention group
Group type: COMPARATOR
Intervention: Obese patients (BMI ≥30 kg/m2) in the TCGA cohort
Number of subjects: 478
Study 31870811 — intervention group
Group type: COMPARATOR
Intervention: Obese patients (BMI ≥30 kg/m2) in the COMPARZ trial
Number of subjects: 478
Study 31870811 — intervention group
Group type: COMPARATOR
Intervention: Obese patients (BMI ≥30 kg/m2) in the MSK immunotherapy cohort
Number of subjects: 478
Study 31870811 — intervention group
Group type: COMPARATOR
Intervention: Tumours of obese patients
Number of subjects: 478
Study 31870811 — intervention group
Group type: COMPARATOR
Intervention: Peritumoral adipose tissue in obese patients
Number of subjects: 478
Study 30741705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive orientation to daily occupational performance (CO‐OP)
Number of subjects: 49
Study 30741705 — intervention group
Group type: COMPARATOR
Intervention: Task‐specific upper extremity training (TUET)
Number of subjects: 49
Study 27815985 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath oil additive
Number of subjects: 60
Study 27815985 — intervention group
Group type: COMPARATOR
Intervention: Non-oil containing skin cleansers
Number of subjects: 60
Study 25344807 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Number of subjects: 169
Study 25344807 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine
Number of subjects: 169
Study 25344807 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Number of subjects: 169
Study 25344807 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 169
Study 25344807 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tenofovir/emtricitabine/rilpivirine
Number of subjects: 169
Study 24337447 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) after first-line therapy
Number of subjects: 36
Study 24337447 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) after second-line therapy
Number of subjects: 36
Study 21295828 — intervention group
Group type: EXPERIMENTAL
Intervention: LIGHT (target liveweight of 70 kg at 161 d of age)
Number of subjects: 64
Study 21295828 — intervention group
Group type: COMPARATOR
Intervention: HEAVY (target liveweight of 100 kg at 161 d of age)
Number of subjects: 64
Study 21295828 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW (gaining liveweight at 0.5 kg/d between 161 and 175 d of age)
Number of subjects: 64
Study 21295828 — intervention group
Group type: COMPARATOR
Intervention: HIGH (gaining liveweight at 1.0 kg/d between 161 and 175 d of age)
Number of subjects: 64
Study 21295828 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW compared to HIGH LW gain
Number of subjects: 64
Study 19514178 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular plaster therapy
Number of subjects: 45
Study 19514178 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 17717132 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP in the highest quartile
Number of subjects: 3225
Study 17717132 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP >3 mg/L in unstable angina/non-ST-elevation myocardial infarction (NSTEMI)
Number of subjects: 3225
Study 17717132 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP >10 mg/L in STEMI
Number of subjects: 3225
Study 17717132 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP concentrations
Number of subjects: 3225
Study 15039514 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional writing
Number of subjects: 37
Study 15039514 — intervention group
Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 37
Study 11524194 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 40
Study 11524194 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40
Study 9591496 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized 17beta‐estradiol (2 mg/d) continuously combined with dydrogesterone (2.5 mg)
Number of subjects: 135
Study 9591496 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized 17beta‐estradiol (2 mg/d) continuously combined with dydrogesterone (5 mg)
Number of subjects: 135
Study 9591496 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized 17beta‐estradiol (2 mg/d) continuously combined with dydrogesterone (10 mg)
Number of subjects: 135
Study 9591496 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized 17beta‐estradiol (2 mg/d) continuously combined with dydrogesterone (15 mg)
Number of subjects: 135
Study 7951368 — intervention group
Group type: EXPERIMENTAL
Intervention: Biken-Cam vaccine (5,000 TCID50/0.5 ml)
Number of subjects: 145